Reproductive Endocrinology And Infertility Clinical Trai

生殖内分泌与不孕不育临床试验

• 批准号: 7334114
• 负责人: James H. Segars
• 金额: --
• 依托单位: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7334114
• 关键词: Reproductive; Endocrinology; Infertility; Clinical; Trai

The Unit on Reproductive Endocrinology and Infertility, led by James Segars, investigates underlying causes and effectiveness of treatment for a variety of clinical reproductive disorders. Our efforts have been focused on uterine leiomyoma (commonly known as fibroids), endometriosis, and reproductive disorders leading to infertility. The unit has the mission to conduct basic, translational, and clinical studies of importance to reproduction in the context of the multi-institutional clinical training program in Reproductive Endocrinology and Infertility. In the past year, we expanded upon our observation that the extracellular matrix of uterine fibroids was abnormally-formed. Based on several studies, our research suggests striking similarities common to fibroid development, keloid formation and altered tissue repair. This has led to the hypothesis that the altered extracellular matrix of uterine fibroids may contribute to fibroid growth. We plan to examine whether compounds that interfere with formation of excessive extracellular matrix similar to that observed in fibroids may have clinical utility. Also in the past year we have concluded a large prospective, randomized, placebo-controlled trial of the selective estrogen receptor modular(SERM), raloxifene, for the treatment of endometriosis-related chronic pelvic pain. This study headed by Dr. Stratton revealed that treatment with raloxifene actually hastened the return to pain in women with endometriosis, indicating that raloxifene, contrary to predictions, was not beneficial in this patient group. Our basic science studies in collaboration with Drs. Chrousos and Kino have revealed that the proto-oncoprotein cloned in our laboratory, Brx, is required for glucocorticoid action in vivo in some instances. This important observation indicates that Brx has a role beyond estrogen action, as initially understood, and may influence the action of other nuclear receptors, suggesting a possible importance for Brx for hormone action in tissues outside the reproductive tract.

由 James Segars 领导的生殖内分泌和不孕症科致力于研究各种临床生殖疾病的根本原因和治疗效果。我们的工作重点是子宫肌瘤（俗称肌瘤）、子宫内膜异位症和导致不孕​​的生殖疾病。该部门的使命是在生殖内分泌学和不孕症多机构临床培训项目的背景下，开展对生殖具有重要意义的基础、转化和临床研究。在过去的一年里，我们进一步观察到子宫肌瘤的细胞外基质形成异常。基于多项研究，我们的研究表明肌瘤发展、疤痕疙瘩形成和组织修复改变之间存在惊人的相似之处。这导致了这样的假设：子宫肌瘤的细胞外基质的改变可能有助于肌瘤的生长。我们计划研究干扰过量细胞外基质形成的化合物是否具有临床实用性，类似于在肌瘤中观察到的情况。同样在过去的一年中，我们完成了一项关于选择性雌激素受体模块 (SERM) 雷洛昔芬的大型前瞻性、随机、安慰剂对照试验，用于治疗子宫内膜异位症相关的慢性盆腔疼痛。斯特拉顿博士领导的这项研究表明，雷洛昔芬治疗实际上加速了患有子宫内膜异位症的女性疼痛的恢复，这表明雷洛昔芬与预测相反，对该患者群体没有益处。我们与博士合作进行基础科学研究。 Chrousos 和 Kino 揭示了我们实验室克隆的原癌蛋白 Brx，在某些情况下是体内糖皮质激素作用所必需的。这一重要的观察结果表明，Brx 的作用超出了最初理解的雌激素作用，并且可能影响其他核受体的作用，这表明 Brx 对于生殖道以外组织中的激素作用可能具有重要意义。